<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847480</url>
  </required_header>
  <id_info>
    <org_study_id>2017/398</org_study_id>
    <nct_id>NCT03847480</nct_id>
  </id_info>
  <brief_title>Dose Painting of Head and Neck Cancer</brief_title>
  <acronym>RADPAINT</acronym>
  <official_title>Dose Painting of Head and Neck Cancer - The RADPAINT Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose-painting may increase the chance of cure at minimised radiation-induced toxicity in
      volumetric-arc radiotherapy (VMAT) for head and neck cancer. This trial (RADPAINT)
      investigates the safety of FDG-PET guided radiotherapy using VMAT dose-painting by contours
      for patients with head and neck cancer of poor prognosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, radiotherapy is planned using 18F-FDG PET/CT (18F-2-fluoro-2-deoxy-D-glucose
      fluorodeoxyglucose positron emission tomography) making one experimental &quot;dose-painting by
      contours&quot; SIB (simultaneous integrated boost) plan with a maximum point dose of 83 Gy. The
      participants will be given 73 Gy and 78 Gy minimum doses to two GTVs (gross tumor volumes
      inside the conventional GTV (68 Gy). GTV_73Gy and GTV_78Gy are determined from the SUV
      (standardized uptake values) from the 18F-FDG PET/CT according to the formula proposed by the
      Ghent group (Van der Straeten et al, R&amp;O -06). It is expected to keep the level of normal
      tissue side-effects within or slightly above the level of conventional radiotherapy (i.e.
      maximum dose of 68 Gy).

      In addition to the routine follow-up, the participants will be examined with 18F-FDG PET/CT
      (3 months after treatment and toxicity scoring at 6 weeks, 6 months, 1 year, 1.5 years and 3
      years after radiotherapy (in addition to the routine follow-up).
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    1 serious adverse event. (Seven patients included.)
  </why_stopped>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late toxicity - mucosal ulcer</measure>
    <time_frame>1 year</time_frame>
    <description>The study will be stopped if ≥ 2 patients experience mucosal ulcers grade ≥ 3 (CTCAE v 3.0/v4.0) without healing within the first year after radiotherapy. This endpoint will be assessed by clinical examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute or late toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Any life-threatening toxicity (CTCAE v4.0) related to radiotherapy. This endpoint will be assessed by clinical examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>&lt; 3 months after radiotherapy</time_frame>
    <description>CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional control</measure>
    <time_frame>3 years</time_frame>
    <description>FDG PET/CT at 3 months. Imaging thereafter if clinical progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
    <description>FDG PET/CT at 3 months. Imaging thereafter if clinical progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Date from central registry.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>FDG-PET guided dose painting</intervention_name>
    <description>The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically or cytologically verified invasive squamous cell carcinoma of the head and
        neck region; Oral cavity, hypopharynx cancer, larynx cancer and HPV ((human papillomavirus)
        negative oropharyngeal cancer.

        Patients planned for standard curative treatment (radical radiotherapy with or without
        concomitant chemotherapy, with nimorazole hypoxic cell radiosensitizer)

        Planned treatment at the Oslo University Hospital

        Age &gt; 18 years

        WHO (World Health Organization) performance status 0-2

        Exclusion Criteria:

        TNM (primary tumor, regional nodes, metastasis) stage cT1 cN0-N1 cM0

        Glottic cancer cT1-T2 cN0 cM0

        HPV positive oropharyngeal carcinoma

        Cancer in the soft palate

        Diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stein Kaasa, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>https://helseforskning.etikkom.no/prosjekterirek/prosjektregister/prosjekt?p_document_id=821377&amp;p_parent_id=832369&amp;_ikbLanguageCode=us</url>
    <description>Link to The Regional Committee for Medical and Health Research Ethics</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Einar Dale</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Dose painting</keyword>
  <keyword>18F-FDG</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

